Pharmafile Logo

Communiqué Awards 2016: Excellence in Communication of Survey or Market Research Data

July 13, 2016 | Communiqué Awards, Lucid 

The winning programme – Treating beyond symptoms in IBD: The Steroid Assessment Tool.

Our approach to medical education is really helping to improve patient outcomes and change lives.

Inflammatory bowel disease (IBD) affects more than 250,000 patients in the UK. Treatment strategies have progressed to treating beyond the symptoms of IBD, aiming to reduce mucosal inflammation, sustain remission and prevent bowel damage. 

Steroids have a place in the treatment pathway but do not sustain remission and are associated with significant side effects.The European Crohn’s and Colitis Organisation (ECCO) defines appropriate steroid use and recommends an exit strategy for steroid-dependent patients. However, gastroenterologists are not aware that inappropriate steroid use occurs in their own clinical practice.

Using a simple digital tool, UK experts audited their own practice and were surprised to see high steroid use among their patients. The expert group became advocates for change, motivated to share their data, targeting more than 300 UK HCPs with high steroid use, which comprises approximately 22% of UK IBD clinicians. Awareness of inappropriate steroid use, and the changes driven by the self-realisation of the need to optimise steroids, have the potential to impact the care delivered to over 50,000 UK IBD patients.


This content was provided by Lucid Group Communications Limited

Company Details

 Latest Content from  Lucid Group Communications Limited 

Lucid celebrate big wins at PMEA 2015

Success for Lucid at PMEA 2015

Lucid invests in their Futures programme with a new hire

Lucid Group continues their expansion

Janus kinase inhibitors are amongst the most read abstracts at the American College of Rheumatology 2015

Rheumatologists eagerly await trial data for Janus kinase inhibitors

Making a difference to patients with IBD

Changing lives with medical education

Lucid Group showcases new KOL identification and mapping tool

Advancing Expert identification with digital new tool from Lucid Group

Lucid CEO discusses his inspiration and passion for changing patients’ lives

Changing patients' lives with innovative methodologies in medical education

Lucid Group starts new trend for CME in IBD education

A tailored educational event in IBD